Galectin Therapeutics Inc.
GALT
$2.41
$0.010.42%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.85M | 1.43M | 1.59M | 1.36M | 1.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.08M | 3.37M | 4.20M | 4.63M | 7.90M |
| Operating Income | -4.08M | -3.37M | -4.20M | -4.63M | -7.90M |
| Income Before Tax | -5.05M | -5.50M | -8.18M | -7.52M | -9.63M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.05M | -5.50M | -8.18M | -7.52M | -9.63M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.05M | -5.50M | -8.18M | -7.52M | -9.63M |
| EBIT | -4.08M | -3.37M | -4.20M | -4.63M | -7.90M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.08 | -0.09 | -0.13 | -0.12 | -0.15 |
| Normalized Basic EPS | -0.05 | -0.05 | -0.08 | -0.07 | -0.10 |
| EPS Diluted | -0.08 | -0.09 | -0.13 | -0.12 | -0.15 |
| Normalized Diluted EPS | -0.05 | -0.05 | -0.08 | -0.07 | -0.10 |
| Average Basic Shares Outstanding | 65.78M | 64.74M | 64.21M | 63.45M | 63.20M |
| Average Diluted Shares Outstanding | 65.78M | 64.74M | 64.21M | 63.45M | 63.20M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |